Is telomerase a viable target in cancer?

被引：106
作者：
Buseman, C. M. [1 ]
Wright, W. E. [1 ]
Shay, J. W. [1 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA
来源：
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS | 2012年 / 730卷 / 1-2期
关键词：
Senescence; Telomeres; Virotherapy; Immunotherapy; CYTOTOXIC T-LYMPHOCYTES; SUICIDE GENE-THERAPY; ARMED ONCOLYTIC ADENOVIRUS; TUMOR-ASSOCIATED ANTIGEN; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; TEMPLATE ANTAGONIST; PANCREATIC-CANCER; IN-VITRO; POTENTIAL ANTICANCER;
D O I：
10.1016/j.mrfmmm.2011.07.006
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The ideal cancer treatment would specifically target cancer cells yet have minimal or no adverse effects on normal somatic cells. Telomerase, the ribonucleoprotein reverse transcriptase that maintains the ends of human chromosome, is an attractive cancer therapeutic target for exactly this reason [1]. Telomerase is expressed in more than 85% of cancer cells, making it a nearly universal cancer marker, while the majority of normal somatic cells are telomerase negative. Telomerase activity confers limitless replicative potential to cancer cells, a hallmark of cancer which must be attained for the continued growth that characterizes almost all advanced neoplasms [2]. In this review we will summarize the role of telomeres and telomerase in cancer cells, and how properties of telomerase are being exploited to create targeted cancer therapies including telomerase inhibitors, telomerase-targeted immunotherapies and telomerase-driven virotherapies. A frank and balanced assessment of the current state of telomerase inhibitors with caveats and potential limitations will be included. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码：90 / 97
页数：8
相关论文
共 139 条
[1]  
Akiyama M, 2003, CANCER RES, V63, P6187
[2]  
Allan Alison L, 2006, Breast Dis, V26, P87
[3]   Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes [J].
Arai, J ;
Yasukawa, M ;
Ohminami, H ;
Kakimoto, M ;
Hasegawa, A ;
Fujita, S .
BLOOD, 2001, 97 (09) :2903-2907
[4]  
Asai A, 2003, CANCER RES, V63, P3931
[5]   Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study [J].
Bernhardt, S. L. ;
Gjertsen, M. K. ;
Trachsel, S. ;
Moller, M. ;
Eriksen, J. A. ;
Meo, M. ;
Buanes, T. ;
Gaudernack, G. .
BRITISH JOURNAL OF CANCER, 2006, 95 (11) :1474-1482
[6]   Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms [J].
Brennan, Sarah K. ;
Wang, Qiuju ;
Tressler, Robert ;
Harley, Calvin ;
Go, Ning ;
Bassett, Ekaterina ;
Huff, Carol Ann ;
Jones, Richard J. ;
Matsui, William .
PLOS ONE, 2010, 5 (09) :1-8
[7]   Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer [J].
Brunsvig, Paal F. ;
Aamdal, Steinar ;
Gjertsen, Marianne K. ;
Kvalheim, Gunnar ;
Markowski-Grimsrud, Carrie J. ;
Sve, Ingunn ;
Dyrhaug, Marianne ;
Trachsel, Sissel ;
Moller, Mona ;
Eriksen, Jon A. ;
Gaudernack, Gustav .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (12) :1553-1564
[8]   Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines [J].
Bryan, TM ;
Englezou, A ;
DallaPozza, L ;
Dunham, MA ;
Reddel, RR .
NATURE MEDICINE, 1997, 3 (11) :1271-1274
[9]   Telomerase-based immunotherapy of cancer [J].
Carpenter, Erica L. ;
Vonderheide, Robert H. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (10) :1031-1039
[10]   Neural Tumor-Initiating Cells Have Distinct Telomere Maintenance and Can be Safely Targeted for Telomerase Inhibition [J].
Castelo-Branco, Pedro ;
Zhang, Cindy ;
Lipman, Tatiana ;
Fujitani, Mayumi ;
Hansford, Loen ;
Clarke, Ian ;
Harley, Calvin B. ;
Tressler, Robert ;
Malkin, David ;
Walker, Erin ;
Kaplan, David R. ;
Dirks, Peter ;
Tabori, Uri .
CLINICAL CANCER RESEARCH, 2011, 17 (01) :111-121
12345678910